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North Chicago, IL, United StatesBackground & Aims: Hepatitis C virus (HCV)-infected patients
with a history of injection drug use have low rates of initiation
and completion of interferon-based therapies. This study evalu-
ated efﬁcacy, safety, and pharmacokinetics of a 12-week all-oral
regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir + rib-
avirin in HCV genotype 1-infected patients on stable opioid
replacement therapy.
Methods: This was a phase II, multicenter, open-label, single-arm
study in treatment-naïve or peginterferon/ribavirin
treatment-experienced HCV genotype 1-infected patients on
methadone or buprenorphine ± naloxone. Patients received
12 weeks of co-formulated ombitasvir/paritaprevir/ritonavir
(25 mg/150 mg/100 mg once daily) and dasabuvir (250 mg twice
daily) + weight-based ribavirin. The primary efﬁcacy endpoint
was sustained virologic response 12 weeks post-treatment.
Results: Thirty-eight non-cirrhotic patients on chronic metha-
done (n = 19) or buprenorphine (n = 19) were enrolled. A total
of 37 patients (97.4%) had a sustained virologic response
12 weeks post-treatment. No patient had a viral breakthrough
or relapse. One patient discontinued due to serious adverse
events unrelated to study drug (cerebrovascular accident andJournal of Hepatology 20
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polypeptide 1B3.sarcoma). The most frequent adverse events were nausea, fatigue,
and headache. Eight patients had on-treatment hemoglobin con-
centrations <10 g/dl. Pharmacokinetic analyses indicated no clin-
ically meaningful impact of methadone or buprenorphine on
ombitasvir, paritaprevir, ritonavir, dasabuvir, or dasabuvir M1
metabolite exposures. No dose adjustments of methadone or
buprenorphine were required.
Conclusions: The interferon-free regimen of ombitasvir/parita
previr/ritonavir and dasabuvir + ribavirin for 12 weeks was well
tolerated and achieved sustained virologic response in 97.4% of
patients on opioid substitution therapy in this study. This
all-oral regimen may provide an effective alternative to
interferon-based therapies for HCV-infected patients with a his-
tory of injection drug use.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Injection drug use is the main source of hepatitis C virus (HCV)
infections in industrialized nations [1]. Worldwide, approxi-
mately 10 million people who inject drugs (PWID) have been
infected [2], with a global prevalence among long-term injection
drug users of 64–94% [3,4]. Compounding this problem, rates of
treatment initiation for HCV-infected PWID have been reported
to be under 10% [5–7]. Among the small portion of PWID who
do initiate treatment, response rates are limited by a high fre-
quency of discontinuation related to interferon toxicity [8–13].
Thus, interferon-free regimens of direct-acting antivirals with
improved efﬁcacy and tolerability may be crucial in increasing
the rate of successful treatment in this population.
Paritaprevir (formerly ABT-450) is a NS3/4A protease inhibitor
that was identiﬁed by AbbVie and Enanta as a lead compound
for clinical development. Co-administration with ritonavir, an
inhibitor of the cytochrome P-450 enzyme CYP3A4, increases
the peak, trough, and overall plasma concentrations of15 vol. 63 j 364–369
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paritaprevir, resulting in high paritaprevir exposures with once
daily dosing [14]. When administered with ritonavir to previ-
ously untreated genotype 1-infected patients, 3 days of paritapre-
vir monotherapy decreased mean plasma HCV RNA levels by
approximately 4 log10 IU/ml [15]. Ombitasvir (formerly
ABT-267) is a NS5A inhibitor; 3 days of ombitasvir monotherapy
decreased mean HCV RNA levels by approximately 3 log10 IU/ml
[16]. Ombitasvir, paritaprevir, and ritonavir have been
co-formulated into a single ﬁxed-dose tablet (ombitasvir/pari-
taprevir/r). Dasabuvir (formerly ABT-333) is a non-nucleoside
NS5B polymerase inhibitor; 3 days of dasabuvir monotherapy
decreased mean HCV RNA levels by approximately 1 log10 IU/ml
[17].
The combination of these three direct-acting antiviral agents
plus ribavirin was well tolerated in clinical trials, and resulted
in high sustained virologic response rates in genotype
1-infected patients in the absence of exogenous interferon [18–
20]. In phase III trials, 12 weeks of treatment with ombitasvir/-
paritaprevir/r and dasabuvir plus ribavirin resulted in sustained
virologic response rates 12 weeks post-treatment of 96% in both
previously untreated and treatment-experienced patients with-
out cirrhosis [18,20]. One percent or less of patients in these trials
discontinued treatment due to adverse events [18,20]. The study
presented here examined the efﬁcacy, safety, and pharmacoki-
netics of this multi-targeted regimen in HCV genotype
1-infected patients on chronic opioid replacement therapy with
either methadone or buprenorphine.Patients and methods
Patients
Patients were screened and enrolled at eight sites in the United States beginning
in April 2013. Eligible patients were 18–70 years of age and had a body mass
index P18 and <38 kg/m2, chronic HCV genotype 1 infection, plasma HCV RNA
>10,000 IU/ml, and absence of cirrhosis. Patients were treatment-naïve or pegin-
terferon/ribavirin treatment-experienced, and on a stable opioid replacement
therapy of methadone or buprenorphine ± naloxone for at least 6 months before
screening. Patients had no evidence of HIV or hepatitis B coinfection and no liver
disease due to causes other than HCV. All patients signed an informed consent
form. The study was conducted in accordance with the protocol, International
Conference on Harmonisation guidelines, applicable regulations and guidelines
governing clinical study conduct, and the ethical principles that have their origin
in the Declaration of Helsinki.
Study design
This was a phase II, multicenter, open-label, single-arm study. All patients
received ombitasvir/paritaprevir/r 25 mg/150 mg/100 mg once daily and dasabu-
vir 250 mg twice daily for 12 weeks. Ribavirin was dosed twice daily at 1000 mg
total daily dose for patients <75 kg or 1200 mg total daily dose for patients
P75 kg. Patients were followed for 48 weeks after the end of the treatment per-
iod. The study protocol was developed by the investigators and AbbVie. All
authors had access to the data and participated in data analysis and preparation
of the manuscript.
Efﬁcacy assessments
Plasma HCV RNA levels were determined by a central laboratory using the Roche
COBAS TaqMan real-time reverse transcriptase-polymerase chain reaction
assay v2.0. The lower limit of detection (LLOD) of this assay is 15 IU/ml and the
lower limit of quantitation (LLOQ) is 25 IU/ml. HCV genotype and subtype were
assessed from a plasma sample collected at screening using the Versant HCV
Genotype Inno-LiPA Assay, version 2.0 (LiPA; Siemens Healthcare Diagnostics,
Tarrytown, NY). Samples for HCV RNA measurement were collected at screening,Journal of Hepatology 201study day 1, weeks 1, 2, 4, 6, 8, 10, and 12 (or end of treatment), and at
post-treatment weeks 2, 4, 8, 12, 24, 36, and 48 (or discontinuation). Treatment
was to be stopped if any of the following criteria were met: a conﬁrmed HCV
RNA increase from nadir at any time point during treatment, failure to achieve
HCV RNA < LLOQ by week 6, or conﬁrmed HCV RNA P LLOQ at any point during
treatment after HCV RNA < LLOQ.
Safety analyses
Adverse events were collected from the time of study drug administration until
30 days following the end of study drug administration. Serious adverse events
were collected from the time of signing of the informed consent form through
the end of the study. Adverse events were coded using the Medical Dictionary
for Regulatory Activities (MedDRA). The investigator assessed the severity of
each adverse event and its relationship to the use of study drug. Clinical labora-
tory testing occurred at all treatment period visits and at post-treatment weeks 4
and 48, or at the time of study discontinuation.
Steady-state pharmacokinetic analyses
Blood samples for the determination of dasabuvir, dasabuvir M1 metabolite,
ombitasvir, paritaprevir, ritonavir, and ribavirin concentrations were collected
approximately 2, 4, 6, and 24 hours post-dosing at a visit at least 2 weeks
after the start of treatment, from those patients who gave consent for
intensive pharmacokinetic sampling. The Medication Event Monitoring
System (MEMS) caps were used to obtain daily dosing histories for dasabuvir,
ombitasvir/paritaprevir/ritonavir, and ribavirin for all patients. Plasma samples
were processed and assayed according to validated bioanalytical methods.
Plasma concentrations of dasabuvir, dasabuvir M1 metabolite, ombitasvir,
paritaprevir, ritonavir, and ribavirin were determined using a validated
liquid chromatography method with tandem mass spectrometric detection
with LLOQ of 4.58, 4.77, 0.462, 0.601, 4.93, and 98.1 ng/ml, respectively.
Individual blood concentrations of S-methadone, R-methadone, buprenorphine,
norbuprenorphine, and naloxone were not measured.
Statistical assessments
The primary endpoint was the percentage of patients with sustained virologic
response 12 weeks post-treatment, deﬁned as HCV RNA < LLOQ 12 weeks after
the last dose of study drugs. Secondary endpoints included the percentage of
patients with virologic failure during treatment (conﬁrmed HCV RNAP LLOQ
after HCV RNA < LLOQ during treatment or conﬁrmed HCV RNAP LLOQ at the
end of treatment) and the percentage of patients with post-treatment relapse
(conﬁrmed HCV RNAP LLOQ between end of treatment and 12 weeks after the
last dose of study drugs among patients completing treatment with HCV
RNA < LLOQ at the end of treatment). Additional efﬁcacy endpoints included per-
centage of patients with end of treatment response, deﬁned as HCV RNA < LLOQ
at week 12, sustained virologic response 4 weeks post-treatment, and sustained
virologic response 24 weeks post-treatment. All analyses were performed on all
patients who enrolled and received at least one dose of study drugs. SAS (SAS
Institute, Inc., Cary, NC) for the UNIX operating system was used for all analyses.
All conﬁdence intervals were 2-sided with an a level of 0.05.
From the intensive pharmacokinetic data, maximum observed plasma con-
centration (Cmax) and area under the plasma concentration-time curve (AUC) dur-
ing a dosing interval (AUC12 for twice daily administration; AUC24 for once daily
administration), and time to Cmax (Tmax) were summarized. Intensive pharma-
cokinetic data analyses were performed by non-compartmental methods using
Phoenix WinNonlin Version 6.0 (Pharsight, A Certara Company, St. Louis, MO).Results
Patients
Seventy-ﬁve patients were screened and 38 were enrolled. The
most common reasons for exclusion were abnormal laboratory
analysis results (16 patients, 7 of whom had hemoglobin less
than the lower limit of normal), positive urine drug screen for
barbiturates, amphetamines, cocaine, benzodiazepines, phency-
clidine, propoxyphene, or alcohol (7 patients), and lack of veriﬁed5 vol. 63 j 364–369 365
Screened (n = 75)
Reasons for screen failure 
(all reasons) (n = 37)
• meeting inclusion/exclusion 
criteria (n = 36)
• Other (n = 2) 
Enrolled (n = 38)
Completed study drug (n = 37)
Discontinued study drug (n = 1)
• Adverse event (n = 1)
Analyzed (n = 38)
Fig. 1. Patient disposition. Numbers of patients who were screened, enrolled,
completed study drug, and included in analyses are shown.
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Fig. 2. Virologic response rates. Rates of virologic response among all patients
receiving ombitasvir/paritaprevir/r and dasabuvir plus ribavirin are shown.
Numbers above the bars are rates of response. Numbers at the top of each bar
are the number of patients with a response over the total number of patients.
EOTR, end of treatment response; SVR4, sustained virologic response 4 weeks
post-treatment; SVR12, sustained virologic response 12 weeks post-treatment;
SVR24, sustained virologic response 24 weeks post-treatment.
Table 1. Demographic and clinical characteristics of patients at baseline.
N = 38
Male, n (%) 25 (65.8)
White race, n (%) 36 (94.7)
Hispanic or latino ethnicity, n (%) 1 (2.6)
Mean age, yr 48.2 ± 11.0
Mean BMI, kg/m2 27.0 ± 3.9
Mean HCV RNA level, log10 IU/ml 6.58 ± 0.70
IL28B non-CC genotype, n (%) 26 (68.4)
Fibrosis stage, n (%)
   F0-F1
   F2
   F3
30 (78.9)
6 (15.8)
2 (5.3)
HCV genotype 1a, n (%) 32 (84.2)
Treatment-naïve, n (%) 36 (94.7)
Opioid replacement therapy, n (%)
   Methadone
   Buprenorphine
19 (50.0)
19 (50.0)
Plus-minus values are mean ± SD.
Fibrosis stage was determined by liver biopsy (and was scored with the use of the
Metavir, Batts–Ludwig, Knodell, International Association for the Study of the
Liver, Scheuer, Laennec, or Ishak scoring system) or with the use of FibroScan or
FibroTest. Scores range from F0 (no ﬁbrosis) to F4 (cirrhosis). Scoring details are
provided in Table S2 in the Supplementary data.
Research Articleinfection with HCV genotype 1 (7 patients). Additional details of
patients not meeting inclusion/exclusion criteria are in
Supplementary Table 1. All enrolled patients received at least
one dose of study drug (Fig. 1). The ﬁnal date for data collection
for analysis of sustained virologic response 12 weeks
post-treatment was December 23, 2013. Patients were predomi-
nantly white (94.7%) and treatment-naïve (94.7%). Thirty-two of
the 38 patients (84.2%) had HCV genotype 1a infection.
Nineteen patients (50.0%) were on methadone and 19 (50.0%)
were on buprenorphine. Baseline demographic and clinical char-
acteristics of patients are shown in Table 1.366 Journal of Hepatology 201Efﬁcacy
Thirty-seven of the 38 patients (97.4%) achieved sustained viro-
logic response 12 weeks post-treatment. All of these patients also
achieved end of treatment response and sustained virologic
response 4 and 24 weeks post-treatment (Fig. 2). One patient
(2.6%) prematurely discontinued the study after 25 days of treat-
ment due to serious adverse events deemed by the investigator to
be unrelated to study drug treatment. No patient had virologic
failure during treatment or a post-treatment relapse.
Safety
The vast majority of patients (92.1%) experienced at least one
adverse event (Table 2). Most of these events were mild or mod-
erate in intensity, with only three patients (7.9%) experiencing a
severe adverse event. The most common adverse events were
nausea, fatigue, and headache. Two patients (5.3%) experienced
serious adverse events, including one with cerebrovascular acci-
dent and sarcoma who withdrew from the study after 25 days
of treatment. No other patients discontinued study drug due to
adverse events. A second patient had a serious adverse event of
acute myeloid leukemia reported 26 days post-treatment; this
patient remained on study and achieved a sustained virologic
response. None of these serious adverse events were considered
related to study drug by the investigator.
Eight patients (21.1%) experienced a serum hemoglobin level
<10 g/dl while on treatment, including two with a hemoglobin
level <8.0 g/dl (grade 3). Ribavirin dosage was reduced for 6 of
these patients, one of whom also received a blood transfusion.
There were no virologic failures among these 6 patients, although
one withdrew prematurely from the study as described above.
One patient had a grade 3 elevation in total bilirubin (maximum
value 5.8 mg/dl), which was predominantly of indirect bilirubin
and improved with continued study drug administration. No
patient discontinued study drug due to bilirubin elevation or
other laboratory abnormalities. No patient required a change in5 vol. 63 j 364–369
Table 3. Steady-state pharmacokinetic parameters in patients receiving
ombitasvir/paritaprevir/r and dasabuvir plus ribavirin and buprenor-
phine ± naloxone or methadone.
 Drug Geometric mean (%CV)
Cmax (ng/ml) Tmax* (h) AUC
† (ng.h/ml)
Dasabuvir‡ 666 (44%) 4.1 (4.2 ± 2.2) 4797 (45%)
Dasabuvir 
M1 
metabolite
374 (58%) 4.1 (4.5 ± 0.95) 2435 (63%)
Ombitasvir 95 (31%) 4.3 (4.9 ± 1.0) 1438 (31%)
Paritaprevir 1353 (124%) 4.3 (5.5 ± 4.3) 14,066 (129%)
Ritonavir 947 (53%) 4.3 (5.5 ± 4.3) 10,977 (56%)
Ribavirin‡ 3180 (30%) 3.6 (4.7 ± 3.7) 31,984 (31%)
CV, coefﬁcient of variation; Cmax, maximum observed plasma concentration; Tmax,
time to Cmax; AUC, area under the plasma concentration-time curve. *Tmax is
presented as median (arithmetic mean ± standard deviation). AUC = AUC24 for
drugs administered once daily or AUC12 for drugs administered twice daily and
the dasabuvir M1 metabolite. Drug administered twice daily.
Table 2. Adverse events.
Event, n (%) N = 38
Any adverse event 35 (92.1)
Severe adverse event 3 (7.9)
Serious adverse event 2 (5.3)
Adverse event leading to study drug 
discontinuation
1 (2.6)
Common adverse events
Nausea 19 (50.0)
Fatigue 18 (47.4)
Headache 12 (31.6)
Insomnia 7 (18.4)
Rash 6 (15.8)
Anxiety 5 (13.2)
Arthralgia 5 (13.2)
Anemia 4 (10.5)
Irritability 4 (10.5)
Vomiting 4 (10.5)
Common adverse events were those that occurred in >10% of patients during
treatment.
JOURNAL OF HEPATOLOGYthe dosage of methadone or buprenorphine during study
treatment.
Pharmacokinetics
A total of 22 of the 38 enrolled patients gave consent for intensive
pharmacokinetic blood sampling. Twelve of these patients were
on stable opioid replacement therapy of buprenorphine ± nalox-
one and 10 were on methadone. The steady-state pharmacoki-
netic parameters of dasabuvir, dasabuvir M1 metabolite,
ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin are
shown in Table 3. The steady-state exposures for ombitasvir, par-
itaprevir, and ritonavir in the present study were comparable to
exposures observed in previous phase I studies of adults receiving
similar formulations of ombitasvir/paritaprevir/ritonavir and
dasabuvir without methadone or buprenorphine, while expo-
sures of dasabuvir and dasabuvir M1 were slightly lower.Journal of Hepatology 201Discussion
Worldwide, HCV is a major cause of liver-related morbidity and
mortality secondary to cirrhosis, end-stage liver disease, and hep-
atocellular carcinoma. Globally, 10 million PWID are estimated to
be infected [2]; however, the majority of these patients remain
untreated, with uptake rates for interferon-containing regimens
of less than 10 percent and high rates of treatment discontinua-
tion [5–7,12,13]. While lack of diagnosis and access to care are
signiﬁcant factors contributing to this low rate of treatment,
the real and perceived side effects of interferon-based treatment
also play a role [21,22]. PWID may be dissuaded from seeking
treatment based on information about the difﬁculties of inter-
feron therapy obtained from peer networks [23]. The potential
impact of interferon side effects on employment has also been
identiﬁed as a barrier to treatment in this population [23]. In
addition, PWID often have comorbidities such as depression,
which make them poor candidates for interferon therapy.
Improved treatment uptake and completion rates could sig-
niﬁcantly decrease the burden of liver disease in this underserved
patient population, since sustained virologic response is associ-
ated with a lower risk of HCV-related clinical outcomes [24].
Furthermore, although patients who have acquired HCV through
a blood transfusion in the distant past are unlikely to transmit to
others, those with a history of injection drug use remain a con-
stant reservoir of potential transmission through relapse of sub-
stance abuse with unsafe injection practices. Mathematical
models suggest that increased uptake of treatment among this
patient population could substantially reduce HCV infection inci-
dence and prevalence, leading to tangible beneﬁts for overall
public health [25,26].
In this phase II, multicenter study of a 12-week regimen of
ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV
genotype 1 infected patients receiving opioid replacement ther-
apy, 97.4% (37/38) of patients achieved sustained virologic
response through 24 weeks post-treatment. No viral break-
throughs or relapses were observed with this multi-class
approach to HCV treatment.
The virologic responses and low rate of discontinuation seen
in this study were consistent with results from phase III trials
evaluating this regimen, in which sustained virologic response
rates of 96% were observed in treatment-naïve and peginter-
feron/ribavirin treatment-experienced patients who were not
on opioid replacement therapy [18,20]. Furthermore, low rates
of reinfection among PWID who undergo successful HCV treat-
ment (one to ﬁve percent per year) have been reported [25].
The phase II data reported here along with these low observed
rates of reinfection suggest that a history of injection drug use
should not be perceived as a barrier to HCV care and manage-
ment by providers [21,25,27,28].
In this study, ombitasvir/paritaprevir/r and dasabuvir plus rib-
avirin was generally well tolerated. Only one patient discontin-
ued treatment prematurely, due to adverse events unrelated to
study drug, and adverse events were generally mild or moderate.
A grade 3 bilirubin elevation observed in one patient was pre-
dominantly indirect bilirubin, consistent with the known effect
of paritaprevir on the bilirubin transporters OATP1B1 and
OATP1B3 and the contribution of ribavirin and its associated
hemolytic anemia [29,30].
The frequency of hemoglobin values <10 g/dl was numerically
greater in the current study compared to that seen in phase III5 vol. 63 j 364–369 367
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trials of this regimen in genotype 1-infected patients who were
not on opioid replacement therapy (21.1% vs. 5.1–5.8%) [18,20].
This appears to be related to lower baseline hemoglobin levels
in the current study compared to the previous studies (mean
value 14.01 g/dl vs. 14.76-14.88 g/dl) since mean hemoglobin
decreases were comparable (2.09 g/dl vs. 2.33 to 2.52 g/dl).
The frequency of ribavirin dose modiﬁcation was correspondingly
greater in the current study, but SVR12 rates were not affected by
ribavirin dose modiﬁcation in this study or in previous studies
[18,20].
Drug-drug interactions are a potential concern in patients on
opioid replacement who are receiving direct-acting antiviral
therapy. In this study, the high efﬁcacy rates and low rates of dis-
continuation due to adverse events suggest that drug-drug inter-
actions did not impact HCV treatment or opioid maintenance. The
exposures of dasabuvir, dasabuvir M1 metabolite, ombitasvir,
paritaprevir, and ritonavir in the current study were comparable
to or slightly lower than the exposures observed in phase I
studies of healthy volunteers receiving the HCV treatment
alone. Drug-drug interaction studies in healthy volunteers not
infected with HCV have also demonstrated a lack of effect of
ombitasvir/paritaprevir/ritonavir and dasabuvir on methadone
and buprenorphine ± naloxone as assessed by opioid pharmaco-
dynamics, Pupillometry, Short Opiate Withdrawal Scale, and
Desire for Drugs Questionnaire [31,32]. While no data are avail-
able to assess the effect of ribavirin on buprenorphine ± naloxone
or methadone, drug-drug interactions are not anticipated as
ribavirin does not affect cytochrome P450-mediated
metabolism and consequently does not interact with
the metabolism of ombitasvir/paritaprevir/ritonavir and
dasabuvir, or metabolism of opioid replacement therapies
[33,34]. The lack of observed drug-drug interactions in the
current and previous studies suggests that no dose adjustment
of methadone, buprenorphine ± naloxone, or HCV treatment is
needed in patients on stable opioid replacement therapy and
ombitasvir/paritaprevir/ritonavir and dasabuvir plus ribavirin.
Limitations of this study include the small sample size and
selected patient population. Only patients receiving stable
opioid substitution therapy were enrolled, effectively excluding
those with active injection drug use. The latter is an important
population that deserves further study. In addition, patients
with cirrhosis were excluded from this study. However, 380
patients with cirrhosis were enrolled in a dedicated phase III
trial of this treatment regimen, which demonstrated sustained
virologic response rates of 92% and 96% following 12 or
24 weeks of treatment, respectively [35]. In addition, the
current study was conducted prior to the availability of data
from phase III trials evaluating the ombitasvir/paritaprevir/r
and dasabuvir regimen ± ribavirin. Those trials demonstrated
that genotype 1b-infected patients without cirrhosis treated
with ombitasvir/paritaprevir/r and dasabuvir do not require
ribavirin, since the regimen minus ribavirin achieved sustained
virologic response rates of 100% in treatment-naïve and
treatment-experienced genotype 1b-infected patients [36–38].
The efﬁcacy of the ombitasvir/paritaprevir/r and dasabuvir
regimen minus ribavirin in genotype 1b-infected patients
receiving stable opioid substitution therapy was not evaluated
in this trial.
With the low interferon-based treatment uptake rates
observed in PWID [5–7], few HCV-infected individuals in this368 Journal of Hepatology 201population achieve sustained virologic response. Opioid substitu-
tion therapy clinics may be an ideal setting to implement all-oral,
interferon-free therapies for patients with HCV genotype 1 infec-
tion. These therapies have the potential to substantially limit dis-
ease progression and reduce transmission among patients with a
history of injection drug use. The results of this study suggest that
a 12-week regimen of ombitasvir/paritaprevir/r and dasabuvir
plus ribavirin may be a suitable treatment option for this popula-
tion. Given the burden of disease and pending availability of bet-
ter tolerated and more efﬁcacious regimens, greater efforts
should be undertaken to screen, evaluate, and treat
HCV-infected patients with a history of drug use [39].Conﬂict of interest
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